Valter Torri
#134,643
Most Influential Person Now
Researcher
Valter Torri's AcademicInfluence.com Rankings
Valter Torriengineering Degrees
Engineering
#4766
World Rank
#5986
Historical Rank
Electrical Engineering
#1247
World Rank
#1337
Historical Rank
Valter Torricomputer-science Degrees
Computer Science
#6113
World Rank
#6444
Historical Rank
Computational Linguistics
#994
World Rank
#1008
Historical Rank
Machine Learning
#1877
World Rank
#1902
Historical Rank
Artificial Intelligence
#2124
World Rank
#2160
Historical Rank
Download Badge
Engineering Computer Science
Valter Torri's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Valter Torri Influential?
(Suggest an Edit or Addition)Valter Torri's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. (1998) (4133)
- Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. (2008) (1928)
- Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. (2009) (1319)
- Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. (2010) (1318)
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (1995) (882)
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial (2003) (767)
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) (642)
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. (2016) (639)
- Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. (1994) (627)
- Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. (2003) (605)
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (2018) (557)
- Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. (2008) (543)
- Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. (1998) (525)
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. (2003) (466)
- Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. (2013) (463)
- Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials (1998) (431)
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study (2020) (419)
- International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma. (2003) (411)
- Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. (2009) (376)
- Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). (2000) (376)
- Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. (2016) (374)
- Results of the European Glaucoma Prevention Study. (2005) (326)
- Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. (2007) (325)
- Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients (2001) (324)
- Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. (2007) (303)
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade (2018) (287)
- Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. (2004) (269)
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. (2015) (263)
- Elevated cerebrospinal fluid levels of monocyte chemotactic protein‐1 correlate with HIV‐1 encephalitis and local viral replication (1998) (262)
- Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis (2006) (262)
- International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. (2003) (254)
- Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta‐analysis (2010) (240)
- Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer (2007) (233)
- CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. (2009) (227)
- Conservative surgery for Stage I ovarian carcinoma in women of childbearing age (1997) (204)
- Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. (2009) (199)
- External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial (2019) (197)
- Sonographic endometrial thickness: a useful test to predict atrophy in patients with postmenopausal bleeding. An Italian multicenter study (1996) (197)
- Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. (2005) (196)
- Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. (2012) (179)
- Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly (2012) (174)
- High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. (2009) (170)
- Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. (2014) (160)
- Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. (2017) (160)
- Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. (2007) (155)
- Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. (1995) (155)
- Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. (2013) (150)
- Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. (2002) (146)
- Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. (2018) (142)
- Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group (2017) (141)
- Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. (2007) (134)
- Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors (2019) (129)
- A MALT lymphoma prognostic index. (2017) (127)
- Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial. (2003) (125)
- First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence (2002) (124)
- Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. (2008) (122)
- European Glaucoma Prevention Study: Author reply (2005) (121)
- Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients (2014) (118)
- A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). (2011) (114)
- Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. (2003) (114)
- Amyotrophic Lateral Sclerosis Multiprotein Biomarkers in Peripheral Blood Mononuclear Cells (2011) (114)
- Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. (2017) (113)
- Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. (2019) (111)
- Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy. (1994) (111)
- Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. (2017) (110)
- Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials (2008) (110)
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group. (2016) (109)
- Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials (2008) (109)
- A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. (2016) (107)
- A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collabo (2009) (106)
- Olfactory system of highly trained dogs detects prostate cancer in urine samples. (2015) (102)
- Beware of Surrogate Outcome Measures (1996) (101)
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. (2020) (101)
- The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. (1998) (101)
- Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests (1999) (101)
- The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. (2013) (99)
- Malignant peritoneal mesothelioma: a multicenter study on 81 cases. (2010) (96)
- Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. (2000) (94)
- Fluorouracil and folinic acid in colon cancer (1996) (91)
- The European glaucoma prevention study design and baseline description of the participants. (2002) (90)
- Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. (2012) (84)
- Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. (1994) (82)
- Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. (1989) (77)
- Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). (1990) (76)
- Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas (2015) (76)
- The role of attitudes, beliefs, and personal characteristics of Italian physicians in the surgical treatment of early breast cancer. (1991) (75)
- Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper (2014) (75)
- Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study (1996) (74)
- HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research (2016) (72)
- Central corneal thickness in the European Glaucoma Prevention Study. (2007) (71)
- Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at‐risk Italian population (2006) (71)
- Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. (2017) (71)
- Effect of spinal degenerative changes on volumetric bone mineral density of the central skeleton as measured by quantitative computed tomography (2005) (70)
- Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. (2007) (70)
- HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. (2019) (70)
- Antibiotics for preventing respiratory tract infections in adults receiving intensive care. (2000) (69)
- Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial (2020) (68)
- Erratum: The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial (Lancet (2003) 361 (2099-106)) (2003) (67)
- Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. (2013) (67)
- Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. (2014) (66)
- Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). (2011) (62)
- SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. (2012) (62)
- Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. (2015) (60)
- Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. (2010) (59)
- Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images. (2018) (59)
- Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. (1997) (59)
- Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. (1992) (58)
- Randomized clinical trials on medical treatment of glaucoma. Are they appropriate to guide clinical practice? (1992) (58)
- The long-term prognostic significance of repeated blood pressure measurements in the elderly: SPAA (Studio sulla Pressione Arteriosa nell'Anziano) 10-year follow-up. (1999) (56)
- Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. (2022) (55)
- Gastrointestinal Stromal Tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 25, pg iii21, 2014) (2015) (54)
- Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. (2011) (53)
- TERAVOLT: Thoracic Cancers International COVID-19 Collaboration (2020) (53)
- Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study (2014) (52)
- International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. (2003) (51)
- Efficacy of biological agents in metastatic triple-negative breast cancer. (2014) (50)
- EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort (2019) (49)
- Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. (2013) (49)
- Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer (2021) (48)
- A Validated Prediction Model for the Development of Primary Open Angle Glaucoma in Individuals with Ocular Hypertension The Ocular Hypertension Treatment Study Group and the European Glaucoma Prevention Study Group (2008) (48)
- Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study (2016) (48)
- HER‐2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma (2002) (46)
- Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer (2004) (46)
- The Italian version of HoNOS (Health of the Nation Outcome Scales), a scale for evaluating the outcomes and the severity in mental health services (2001) (46)
- Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. (2011) (46)
- Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. (2015) (46)
- Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study (2011) (45)
- Soluble stroma‐related biomarkers of pancreatic cancer (2018) (45)
- Autoimmune disorders in patients affected by celiac sprue and inflammatory bowel disease (2009) (42)
- Analysis of Gene Expression in Early-Stage Ovarian Cancer (2008) (42)
- Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. (2015) (42)
- A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). (2010) (41)
- Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. (2020) (41)
- Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. (2020) (40)
- Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. (2005) (40)
- The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib (2015) (40)
- First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. (1998) (39)
- Selective decontamination of digestive tract (1991) (39)
- Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. (2006) (38)
- Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. (2021) (38)
- Heme catabolism by tumor-associated macrophages controls metastasis formation (2021) (36)
- Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases (2014) (36)
- Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. (2019) (34)
- Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world (2017) (34)
- Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). (2019) (34)
- Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study (2018) (34)
- Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. (2009) (33)
- Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. (2021) (33)
- Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint (2018) (32)
- IgG serology in health care and administrative staff populations from 7 hospital representative of different exposures to SARS-CoV-2 in Lombardy, Italy (2020) (32)
- Differential diagnosis and management of focal ground-glass opacities (2009) (32)
- Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial (2020) (31)
- Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) (2016) (31)
- Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial (2020) (31)
- Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma (2021) (30)
- Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). (2018) (30)
- Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results. (1993) (29)
- Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. (1997) (29)
- A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.E.S. (2008) (29)
- Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic Pain in Cancer Patients (2013) (29)
- Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. (2018) (28)
- Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). (2013) (28)
- Differentiation of Small Adnexal Masses Based on Morphologic Characteristics of Transvaginal Sonographic Imaging (2005) (27)
- Cetuximab for metastatic colorectal cancer. (2009) (27)
- Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors (2015) (27)
- Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial (2022) (27)
- Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. (2004) (27)
- The role of idarubicin in adult acute lymphoblastic leukaemia: from drug resistance studies to clinical application. (1997) (26)
- Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly. (1994) (25)
- Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer (2009) (25)
- DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected]. (2014) (24)
- The prognostic role of tumor size in early breast cancer in the era of molecular biology (2017) (24)
- ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease (2016) (23)
- Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression (2019) (23)
- Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients (2006) (23)
- Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial (2017) (23)
- Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. (2019) (22)
- Cell kinetics of human ovarian cancer with in vivo administration of bromodeoxyuridine. (1994) (21)
- Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. (1996) (21)
- Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project (2019) (21)
- Sudden Death in End Stage Renal Disease: Comparing Hemodialysis versus Peritoneal Dialysis (2017) (21)
- Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. (2020) (21)
- The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. (2014) (21)
- Immunometabolic Status of COVID-19 Cancer Patients (2020) (20)
- Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. (2017) (20)
- Simple, shared guidelines raise the quality of antihypertensive treatment in routine care. (2002) (20)
- BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC) (2019) (20)
- Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how (2020) (20)
- International tailored chemotherapy adjuvant trial: ITACA trial. (2011) (19)
- ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. (2013) (19)
- Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites (1998) (19)
- DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer (2011) (19)
- the impact of definition of primary open-angle glaucoma on the cross-sectional assessment of diagnostic validity of Heidelberg retinal tomography. (2005) (19)
- Inappropriate Halsted mastectomy and patient volume in Italian hospitals. (1993) (18)
- The multi-centre assessment of quality of life: the Interdisciplinary Group for Cancer Care Evaluation (GIVIO) experience in Italy. (1998) (18)
- Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta‐Analysis (2017) (18)
- A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. (2019) (17)
- Efficacy and Safety of Vinorelbine-Capecitabine Oral Metronomic Combination in Elderly Metastatic Breast Cancer Patients: VICTOR-1 Study (2017) (17)
- Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial (2019) (17)
- Assessing assumptions for statistical analyses in randomised clinical trials (2019) (17)
- Early stage ovarian cancer: the Italian contribution to clinical research. An update (2001) (15)
- Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma (2019) (15)
- SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy (2021) (15)
- A limited sampling model for the pharmacokinetics of etoposide given orally (2004) (15)
- Dose intensity analysis in advanced ovarian cancer patients. (1993) (15)
- Prognostic nutritional index as a prognostic marker in glioblastoma: Data from a cohort of 282 Italian patients (2019) (14)
- Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer. (1995) (14)
- Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study (2007) (14)
- Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. (2003) (14)
- Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis (2020) (14)
- Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee. (2014) (13)
- A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) (13)
- The Heidelberg retina tomograph ancillary study to the European glaucoma prevention study: study design and baseline factors (2013) (13)
- The impact of cancer treatment guidelines on actual practice in Italian general hospitals: the case of ovarian cancer. (1990) (13)
- Postoperative Hyperprolactinemia Could Predict Longer Disease-Free and Overall Survival in Node-Negative Breast Cancer Patients (2002) (13)
- The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. (2020) (13)
- Impact of recent legislative bills regarding clinical research on Italian ethics committee activity (2008) (13)
- Prognostic value of CT integrated with clinical and laboratory data during the first peak of the COVID-19 pandemic in Northern Italy: A nomogram to predict unfavorable outcome (2021) (12)
- The effect of changes in intraocular pressure on the risk of primary open-angle glaucoma in patients with ocular hypertension: an application of latent class analysis (2012) (12)
- P31 Salvaging clinical trials forced to terminate early by results of external information (1993) (12)
- Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy. (2017) (12)
- The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. (2018) (12)
- LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion) (2020) (12)
- The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. (2019) (11)
- Sampling variability of computer-aided fractal-corrected measures of liver fibrosis in needle biopsy specimens. (2006) (11)
- Inconclusive messages from equivalence trials in thrombolysis (1999) (11)
- Paclitaxel and cisplatin in ovarian cancer. (2000) (11)
- Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. (2019) (11)
- RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma (2018) (11)
- Survey on the treatment of non-small-cell lung cancer in Italy. (2000) (11)
- The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results (2018) (11)
- Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. (2004) (11)
- Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. (2018) (11)
- The SvO2 study: general design and results of the feasibility phase of a multicenter, randomized trial of three different hemodynamic approaches and two monitoring techniques in the treatment of critically ill patients. The SvO2 Collaborative Group. (1995) (11)
- Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? (2008) (10)
- Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. (2014) (10)
- Isolated optic neuritis and its prognosis for multiple sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination and brain MRI (1996) (10)
- Mortality, sudden death and indication for cardioverter defibrillator implantation in a dialysis population. (2015) (10)
- Phase II Study of Taxol Combined With Ifosfamide and Carboplatin in the Treatment of Stage IIIb–IV Non-Small-Cell Lung Cancer (2003) (9)
- Predictive value of heidelberg retina tomograph parameters for the development of glaucoma in the European glaucoma prevention study. (2015) (9)
- Cyproterone acetate in the therapy of prostate carcinoma. (2005) (9)
- Antibiotic prophylaxis to prevent nosocomial infections in patients in intensive care units: evidence that struggle to convince practising clinicians (2006) (9)
- Epidemic HIV-related Kaposi's sarcoma: a retrospective analysis and validation of TIS staging. GICAT. Gruppo Italiano Collaborativo AIDS e Tumori. (1995) (8)
- Comment on: “Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice” (Magnani P, Conforti A, Zanolin E, Marzotto M and Bellavite P, Psychopharmacology, 2010) (2012) (8)
- A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis (2008) (8)
- Trends in Patterns of Care for Breast Cancer in Italy (1979-1987) (1990) (8)
- Clinical profile of ioversol. A metaanalysis of 57 randomized, double-blind clinical trials. (1996) (8)
- NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). (2013) (8)
- 420 Conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus conventional radiotherapy and concomitant chemotherapy in advanced oropharyngeal carcinoma: A randomized clinical trial (1995) (8)
- Sustained Inhibition of HER 3 and EGFR Is Necessary to Induce Regression of HER 2-Ampli fi ed Gastrointestinal Carcinomas (2015) (8)
- A Joint Model for Prognostic Effect of Biomarker Variability on Outcomes: long-term intraocular pressure (IOP) fluctuation on the risk of developing primary open-angle glaucoma (POAG). (2011) (8)
- Patterns of Care and Survival in Non Small Cell Lung Cancer: 15 Years’ Experience in a General Hospital (1994) (8)
- Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort (2019) (8)
- Patterns of Relapse and Modalities of Treatment of Breast Cancer: The ‘IRIS’ Project, a Multicenter Observational Study (2004) (8)
- Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials (2008) (8)
- Consensus Development Conference: Assessment of the Quality of Life in Cancer Clinical Trials (1992) (7)
- How Tumor Markers are used in the Routine Follow-up of Breast and Colorectal Cancer. A Survey of 29 Italian Hospitals (1998) (7)
- Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer (2019) (7)
- Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study (2019) (7)
- Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study (2020) (7)
- Evaluation of a Primary Open-Angle Glaucoma Prediction Model Using Long-term Intraocular Pressure Variability Data: A Secondary Analysis of 2 Randomized Clinical Trials. (2020) (7)
- Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients (2018) (7)
- Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. (2020) (6)
- Stereotactic body radiation therapy (SBRT) for lung metastases from sarcoma in oligometastatic patients: a phase 2 study. (2022) (6)
- Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials. (2017) (6)
- Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR) (2019) (6)
- Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system (2020) (6)
- Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM) (2018) (6)
- The Glaucoma Italian Pediatric Study (GIPSy): 1-Year Results (2017) (6)
- Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis (2022) (6)
- Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience (2020) (6)
- Abstract S12-03: Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies (2020) (6)
- Early progression of disease predicts shorter survival in patients with mucosa-associated lymphoid tissue lymphoma receiving systemic treatment (2020) (6)
- Neoadjuvant Oxaliplatin-based Chemotherapy for Liver Metastases from Colorectal Cancer. An Italian Survey (2005) (6)
- Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics (2016) (6)
- Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural-economic status, awareness of disease and the relation with the oncologist. (2016) (5)
- 1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program (2020) (5)
- Afatinib for lung cancer: let there be light? (2014) (5)
- DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. (2020) (5)
- Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology (2016) (5)
- Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients. (2014) (5)
- A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry (2022) (5)
- BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer. (2018) (5)
- Final results of a randomized phase II trial (NCT00637975) evaluating activity and toxicity of fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed-dose pregabalin for the treatment of oncologic neuropathic pain (NEUROPAIN-01). (2011) (5)
- International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method. (2018) (5)
- Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study (1998) (5)
- Cost of Insurance Policies for Investigator-Initiated Cancer Clinical Trials in Italy (2005) (5)
- Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction? (2015) (5)
- Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration. (2018) (5)
- International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung Cancer. (2021) (5)
- Relationship between response and survival in patients with advanced ovarian cancer. (1992) (4)
- Highly-Trained Dogs ’ Olfactory System Detects Prostate Cancer in Urine Samples (2014) (4)
- To target or not to target, that is the question. (2013) (4)
- Effectiveness of adjuvant fluorouracil in elderly colon cancer patients: the internal and external validity of nonrandomized research design. (2003) (4)
- Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study. (2013) (4)
- Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (2021) (4)
- Sidedness influences prognosis in colon cancer patients receiving an adjuvant therapy. A GISCAD analysis from three randomized trials including 5234 patients. (2017) (4)
- Glioblastoma Multiforme In Elderly Population (2012) (4)
- LBA21_PRProspective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy) (2017) (4)
- How CA 125 Is Used in the Routine Follow-Up of Ovarian Cancer:A Survey of 29 Italian Hospitals (1998) (4)
- Assessing the effectiveness of follow-up care for colorectal cancer: a great conceptual and methodological challenge for clinical oncology. (1997) (4)
- 603 Prospective evaluation of the prognostic value of p53, K-ras, Ki67 in radically resected non-small cell lung cancers randomized in a clinical trial of adjuvant chemotherapy (ALPI trial) (1997) (4)
- "Re-irradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study. ". (2021) (4)
- Predicting response of molecular targeted therapies: a still possible challenge? (2008) (4)
- IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone. (2015) (4)
- Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. (2012) (4)
- Individual patients data analysis (IPD) of three randomized studies comparing erlotinib (E) with chemotherapy (CT) in patients with advanced wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung cancer (NSCLC). (2015) (4)
- Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse. (2014) (3)
- Prolonged Remission in Adult B-ALL (L3) and Advanced Burkitt’s Lymphoma Using Acute Leukaemia Regimens: Study of 34 Patients (1998) (3)
- Prospective evaluation through questionnaires of the emotional status of cancer patients in the waiting rooms of a department of oncology (2016) (3)
- Meta-analysis of Individual-patient Survival Data Using Random-effect Models (2000) (3)
- Paclitaxel plus bevacizumab for metastatic breast cancer. (2008) (3)
- Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM) (2016) (3)
- Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study (2021) (3)
- Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study (2021) (3)
- A proposal for a new approach to intergroup cancer trials. (1995) (3)
- Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations? (2014) (3)
- LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial (2020) (3)
- Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis (2018) (3)
- Standardization of EGFR FISH in colorectal cancer: Results of an international, interlaboratory reproducibility ring study. (2011) (3)
- Tumor‐associated macrophages and risk of recurrence in stage III colorectal cancer (2022) (3)
- Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated malignant pleural mesothelioma (MPM) patients: Italian SoMe Study. (2011) (3)
- ACTION + ICON1: two parallel randomised phased III trials comparing adjuvant chemotherapy to no adjuvant chemotherapy following surgery in women with high risk early ovarian cancer (2001) (3)
- Bevacizumab for non-small-cell lung cancer. (2007) (3)
- Factors Affecting Mortality in 1022 COVID-19 Patients Referred to an Emergency Department in Bergamo during the Peak of the Pandemic (2020) (3)
- Late-Breaking Abstracts (2019) (3)
- Insurance for independent cancer trials. (2004) (2)
- 507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer (2020) (2)
- Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088) (2020) (2)
- Antibiotics for preventing respiratory tract infections in adults receiving intensive care. (2000) (2)
- Dipyridamole stress echocardiography in diagnosis and prognosis of hemodialysis patients with asymptomatic coronary disease (2011) (2)
- AB053. PS02.17: The TYME network of expert centres presents the first Italian consensus conference for thymic epithelial tumours (2017) (2)
- EGFR mutations and EGFR tyrosine kinase inhibitors. (2015) (2)
- Relationship of tumor response and survival in advanced ovarian cancer patients treated with chemotherapy (1991) (2)
- Central Corneal Thickness in the European Glaucoma Prevention Study (EGPS) (2005) (2)
- Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study. (2018) (2)
- SCHARP Survival Curve and Hazard Ratio Program (1998) (2)
- EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT (2019) (2)
- 6535 POSTER Predictive role of biological markers in NSCLC patients (pts) treated with EGFR tyrosine kinase inhibitors (TKIs): a metanalysis of randomized trials (2007) (2)
- Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC (2022) (2)
- Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma). (2009) (2)
- Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Final results of the VICTOR-6 study. (2018) (2)
- Do we need biopsies of metastases for colorectal cancer patients? (2009) (2)
- Follow-up in Colorectal Cancer (1997) (2)
- Efficacy of biologic agents (BA) in metastatic, triple-negative breast cancer (TNBC): A systematic review. (2011) (2)
- Function of GH/IGF-I axis in aging: Multicenter study in 152 healthy elderly subjects with different degrees of physical activity: Italian Association for Research on Brain Aging (AIRIC) Multicenter Study Group (1997) (2)
- ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit (2003) (2)
- Indolent lymphoma 295 ANALYSIS OF PROGNOSTIC FACTORS IN 424 MALT LYMPHOMA PATIENTS TREATED IN THE IELSG-19 MULTICENTER RANDOMISED STUDY (2011) (2)
- PO64 METRONOMIC CHEMOTHERAPY (CHT) COMBINATION OF VINORELBINE (VRL) AND CAPECITABINE (CAPE) IN HER2- ADVANCED BREAST CANCER (ABC) PATIENTS (PTS) DOES NOT IMPAIR GLOBAL QOL. FIRST RESULTS OF THE VICTOR-2 STUDY (2015) (2)
- Comment on: “Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice” (Magnani P, Conforti A, Zanolin E, Marzotto M and Bellavite P, Psychopharmacology, 2010) (2011) (2)
- Gadoxetate Disodium-Enhanced MR Cholangiography for Evaluation of Biliary-Enteric Anastomoses: Added Value Beyond Conventional T2-Weighted Images. (2019) (2)
- Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial (2022) (2)
- Looking for efficiency rather than efficacy in randomized controlled trials in oncology. (2010) (2)
- Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies (2015) (2)
- The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111). (2004) (2)
- Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR) (2020) (2)
- PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results (2021) (2)
- Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey (2023) (1)
- Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey (2023) (1)
- Effect of selective decontamination of the digestive tract (SSD) upon mortality (1992) (1)
- Approaches to interim analysis of randomized clinical trials in cancer: a survey from the Italian National Monitoring Centre for Clinical Trials (2006) (1)
- Efficacy of Trastuzumab in Unselected Patients with HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis (2014) (1)
- 861P Limited implementation of the ESMO-ESGO (European Society of Gynaecological Oncology)-ESTRO (European Society for Radiotherapy and Oncology) consensus conference recommendations (CCR) on endometrial cancer (EC) (2020) (1)
- Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform (2023) (1)
- 248 Long Term Treatment with an All-oral Metronomic Schedule of Vinorelbine (VRL) and Capecitabine (CAPE) in Metastatic Breast Cancer (BC) Patients (pts). Preliminary Results of Toxicity and Efficacy of the VICTOR-2 Study (2012) (1)
- Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project (2018) (1)
- Abstract CT263: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: The PEGASUS trial (2020) (1)
- Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer. (2016) (1)
- The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer (2019) (1)
- Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: Findings from the 'GISCAD-Alternating schedule' study (2008) (1)
- Erratum: DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosupprossor (Journal of the National Cancer Institute (2014) 106:3 DOI: 10.1093/jnci/dju053) (2014) (1)
- Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. (2022) (1)
- Turn off pain evaluates the quality of pain care provided for paediatric inpatients (2018) (1)
- The impact of chemotherapy on quality of life (QoL) in advanced non-small cell lung cancer. Results of a multicenter phase-III study (1998) (1)
- ICON3 and chemotherapy for ovarian cancer. Authors' reply (2002) (1)
- Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors. (2015) (1)
- Switch maintenance versus second-line treatment in non-small cell lung cancer. (2011) (1)
- Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer (2017) (1)
- Fatigue in Oncology (2012) (1)
- Author Correction: Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study (2020) (1)
- Merkel Cell Carcinoma – Current State and the Future (2016) (1)
- Gefitinib and erlotinib: Same or different tyrosine kinase inhibitors (TKIs)? (2008) (1)
- Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study (2022) (1)
- Validation Of Data Pooling Of The Confocal Scanning Laser Ophthalmoscopy (cslo) As Predictor Of The Onset Of Primary Open Angle Glaucoma (poag) (2011) (0)
- Abstract 2672: Early evaluation of response to Vemurafenib treatment with FDG PET/CT in patients with metastatic melanoma. (2013) (0)
- Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 ( (2022) (0)
- Supplementary Material for: Sudden Death in End Stage Renal Disease: Comparing Hemodialysis versus Peritoneal Dialysis (2017) (0)
- Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy in unfit or older metastatic colorectal cancer patients: A systematic review and pooled-analysis. (2016) (0)
- Implementing clinical practice guidelines: time to assess it (2020) (0)
- ICON2 trial (multiple letter) [1] (1999) (0)
- A systematic review and meta-analysis of early death (ED) upon immune checkpoint inhibitors (ICI) alone or combined with other non-ICIs treatments as first-line treatment of advanced solid tumors. (2022) (0)
- The role of comorbidity on the feasibility and outcome of quality of care and effectiveness studies (1991) (0)
- Abstracts of papers (2005) (0)
- ICION3 and chemotheraphy for avarian camcer (2002) (0)
- Cell kinetics in management of ovarian cancer. (1992) (0)
- 2022-RA-760-ESGO Predictive model of severe complications in patients who underwent an open gynecological cancer surgery on an enhanced recovery after surgery (ERAS) program (2022) (0)
- The above letter was referred to the authors, who respond as follows: (2001) (0)
- Exenatide for type 2 diabetes (2009) (0)
- A randomized phase II trial of maintenance oral metronomic vinorelbine versus close observation in advanced non-small cell lung cancer (NSCLC) following platinum-based chemotherapy: MA.NI.LA. trial. (2018) (0)
- Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial). (2023) (0)
- ·P-35 The impact of management guidelines on quality of breast, colorectal and ovarian cancer in community hospitals (1990) (0)
- Pattern of care and prognosis of lung cancer patients: Fifteen years experience of S. Carlo Hospital Medical Oncology (1993) (0)
- Early progression of disease (POD24) as survival predictor in MALT lymphoma. (2019) (0)
- Abstract OT1-01-05: PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer (2017) (0)
- P035 Sequential targeted therapy with sunitinib-sorafenib (SU-SO) versus sorafenib-sunitinib (SO-SU) in metastatic renal cell carcinoma: Results from a large cohort of patients (2013) (0)
- Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach (2022) (0)
- Abstract P4-12-22: Time to relapse (TTR) is a potential discriminator of clinical outcome in HER2-positive breast cancer (BC) patients (pts) progressing on adjuvant trastuzumab (AdjT) (2013) (0)
- Early FDG PET/CT monitoring of patients with metastatic melanoma undergoing vemurafenib treatment (2013) (0)
- Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial. (2019) (0)
- F32Efficacy and safety of everolimus (eve) and exemestane (exe) in postmenopausal hormone-receptor positive (hr+) advanced breast cancer (abc) patients (pts) beyond clinical trials: preliminary results of the observational multicenter eva study (2016) (0)
- Efficacy of FUFOX regimen in the treatment of a selected population with metastatic colorectal cancer (MCC) (2007) (0)
- Using t he E xpected S urvival t o E xplain D ifferences Between t he R esults o f R andomized T rials: A C ase i n A dvanced O varian C ancer (2003) (0)
- ICON2 trial (1999) (0)
- Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results of the Victor-6 Study (2017) (0)
- Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study (2018) (0)
- Randomized trial of systematic lymphadenectomy (LY) vs nodal sampling (SA) at second look surgery (SLS) in ovarian cancer patients: Final results. (2006) (0)
- 169PNeoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial (2017) (0)
- A model of clinical trial focused on caring procedure: The «Prone-Supine Study» protocol (2000) (0)
- Perspective evaluation of emotional state of oncological patients in the waiting rooms. (2009) (0)
- The natural history of HER2-overexpressing (HER2+) metastatic breast cancer (MBC) treated with trastuzumab (T): Practical points to consider in developing treatment strategies. (2014) (0)
- Abstract 3943: Baseline LDH serum level as predictive value of activity in patients treated with anti PD-1 and PDL-1 monoclonal antibodies (2016) (0)
- In memoriam: Dr. Irene Claudia Floriani (1964–2016) (2016) (0)
- Recursive partition methods for the analysis of prognostic factors in advanced ovarian cancer (1991) (0)
- P09.18 COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT) (2021) (0)
- A Systematic Review and Meta-Analysis on the Optimal Treatment Duration of CHEckpoint InhibitoRS in Solid Tumors: The OTHERS Study (2022) (0)
- To Continue or Not to Continue? That Is the Question. (2020) (0)
- RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. (2019) (0)
- Contents Vol. 71, 2006 (2007) (0)
- Letter to the Editor (2004) (0)
- Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study. (2018) (0)
- The presence of bone (BM) and concomitant non-bone metastases (cNBM) significantly worsens the 2-year overall survival (OS) in breast cancer (BC) patients (PTS): Update of results in the moon study (2005) (0)
- Neuroimaging and Case Reports 3 November 1997, Monday (1997) (0)
- Centre for Statistical and Methodological Excellence (CESAME): A Consortium Initiative for Improving Methodology in Randomised Clinical Trials. (2023) (0)
- Paper1275-25 april 1998 (1998) (0)
- Efficacy of intraportal infusion for colon cancer: a fair assessment? (1991) (0)
- 9085 A platinum based second line rechallenge chemotherapy improves survival in small cell lung cancer patients (2009) (0)
- Abstract P6-11-10: Full-Oral, Metronomic Schedule of Vinorelbine (VNB) and Capecitabine (CAPE) in Locally Advanced or Metastatic Breast Cancer (BC) Patients (Pts): A Single Institution, Dose-Finding Study (2010) (0)
- ICON2 TRIAL. AUTHORS' REPLY (1999) (0)
- 1562P Observational prospective study of Italian guidelines application for patients with pancreatic ductal adenocarcinoma (2020) (0)
- Methodology of clinical research: an overview (2006) (0)
- Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Hines et al. (2016) (0)
- 59A The fallacy of the analysis of treatment effect according to the control group rates in systematic reviews (1995) (0)
- Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR) (2019) (0)
- Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): old drugs, new results. The multicenter VICTOR-6 study. (2017) (0)
- Heidelberg Retina Tomograph (HRT) to Predict the Onset of Open Angle Glaucoma in the European Glaucoma Prevention Study (2011) (0)
- P41 Weeding out bad apples: Monitoring data quality in RCTs (1996) (0)
- P3.02b-009 Plasma and Tissue Inflammatory and Angiogenic Biomarkers to Explore Resistance to EGFR-TKIs and Association with VeriStrat Status: Topic: EGFR Biomarkers (2017) (0)
- 1329TiPA RANDOMIZED PHASE III MULTICENTER TRIAL OF CUSTOMIZED CHEMOTHERAPY VERSUS STANDARD OF CARE FOR 1ST LINE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): THE ELDERLY PATIENT INDIVIDUALIZED CHEMOTHERAPY (EPIC) TRIAL. (2014) (0)
- 378PDISEASE PROGRESSION PATTERN IN METASTATIC BREAST CANCER PATIENTS (MBC) TREATED WITH ANTI-HER2 THERAPIES. (2014) (0)
- How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia (2022) (0)
- CELL KINETICS IN MANAGEMENT OF OVARIAN CANCER. AUTHOR'S REPLY (1993) (0)
- PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach. (2022) (0)
- PP01.01 PEOPLE (NTC03447678), a Phase II Trial to Test Biomarkers of Response to Pembrolizumab as First-Line Treatment in Advanced NSCLC Patients with PD-L1>50% (2023) (0)
- When to stop an ongoing trial: The case of adjuvant chemotherapy on colon cancer (ACCC) (1991) (0)
- Erratum: Relationship between response and survival in patients with advanced ovarian cancer (Journal of National Cancer Inst (1992) 84 (899-900)) (1992) (0)
- Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: short-term and long-term outcomes from the CHECK study – protocol for a randomised, multicentre, phase 3 trial (2022) (0)
- DEMo: A prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy (2019) (0)
- HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression. (2014) (0)
- P66 SAS® macro routines for the monitoring and the analysis of studies requiring prolonged follow-up (1995) (0)
- Antibiotics versus surgery for appendicitis (2011) (0)
- PO75 RETROSPECTIVE ANALYSIS OF ADVANCED LUMINAL BREAST CANCER PATIENTS TREATED WITH ENDOCRINE THERAPY (ET) ANDPALBOCICLIBWITHINACOMPASSIONATE USE PROGRAMME (2017) (0)
- Multimodal evoked potentials in patients affected by retrobulbar optic neuritis (1996) (0)
- Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival (2020) (0)
- Turn off pain: What has changed 4 years later? (2020) (0)
- Evidence-based guidelines: Improving AGREEment on consistence evaluation (2012) (0)
- PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers. (2022) (0)
- Subject Index Vol. 71, 2006 (2007) (0)
- MA03.10 Prospective Evaluation of a Prognostic Clinico-Molecular Score (DEMo) to Predict Outcome of Advanced NSCLC Patients Treated with Immunotherapy (2019) (0)
- A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) (0)
- An imaging study of vemurafenib in patients with BRAFV600-mutated metastatic melanoma. (2017) (0)
- SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in 1 Lombardy , Italy 2 3 (2020) (0)
- Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery for gastric carcinoma at high risk of peritoneal carcinomatosis: short and long-term outcomes (GOETH STUDY)—a collaborative randomized controlled trial by ACOI, FONDAZIONE AIOM, SIC, SICE, and SIC (2022) (0)
- Original Article ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients (2013) (0)
- STYLE (NCT03449173) a phase II Trial of Sunitinib in patients with type B3 Thymoma or Thymic Carcinoma in second and further lines. (2023) (0)
- Critical evaluation of the role of oxaliplatin- and irinotecan-based regimens as first-line chemotherapy in advanced colorectal cancer (CRC). (2006) (0)
- Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR) (2020) (0)
- Subject Index Vol. 63, 2002 (2002) (0)
- Retrospective analysis of patients with male breast cancer: Report from O.R.I.O.N. collaborative group (2008) (0)
- Roleofpunctureandaspiration inexpectantmanagement of simpleovarian cysts: a randomised study (1996) (0)
- The Confocal Scanning Laser Ophthalmoscopy Substudy To The European Glaucoma Prevention Study (EGPS): Study Design and Baseline Factors (2011) (0)
- 481PDSidedness influences prognosis in stage III but not in stage II colon cancer patients receiving an adjuvant therapy: A GISCAD analysis from three randomized trials including 5234 patients (2017) (0)
- 81P Clinical experience with EndoPredict test: Building a clinicopathological model predictive of genomic test result (2022) (0)
- Efficacy and safety of bevacizumab in elderly or unfit patients with metastatic colorectal cancer: A systematic review and meta-analysis. (2016) (0)
- Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma (2022) (0)
- Real-world guideline application in the management of pancreatic cancer patients: the Italian GARIBALDI study. (2019) (0)
- H31KRAS and Ki-67 in Non Small Cell Lung Cancer (2015) (0)
- Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study. (2022) (0)
- Immunometabolic interference between cancer and COVID-19 (2023) (0)
- PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers (2022) (0)
- 1236P Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation (2021) (0)
- Outcomes of small cell lung cancer (SCLC) patients treated with second-line chemotherapy (SL): A retrospective analysis of 166 patients. (2009) (0)
- 301PMetronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Old drugs, new opportunities Preliminary results of the VICTOR-6 study (2017) (0)
- An Oxaliplatin + 5-Fluorouracil Bolus + Folinic Acid (BFOL) Regimen as First-Line Treatment in Metastatic Colorectal Cancer Patients (2007) (0)
- Correlation of longtime efficacy maintenance PARP inhibitor therapy with pre-treatment in a single-institution experience. (2020) (0)
- 1830P Early deaths (ED) upon first-line immunecheckpoint inhibitors (ICI) alone or combined to other non-ICI drugs across solid cancers: A systematic review and meta-analysis (2021) (0)
- Contents Vol. 63, 2002 (2002) (0)
- Methodological issues in screening for relapse in early breast cancer (1992) (0)
- Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study (2018) (0)
- Complications from treatment of localised prostate cancer (2014) (0)
- Abstract CT261: METAMECH -A Master Observational Trial empowering mechanobiology translational research and mechanobased proof of concept trials in breast cancer (2020) (0)
- Evidence-based guidelines for bone metastases? (2017) (0)
- Author Correction: Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study (2020) (0)
- Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint (2018) (0)
- [Explanatory model of the cost variability of treating patients: methodology and results]. (2002) (0)
- The level of HER2/neu gene amplification as predictive factor in patients with metastatic breast cancer treated with a trastuzumab-based therapy (2008) (0)
- The Effect of IOP and Other Inter-Current Factors on the Development of Open Angle Glaucoma in the European Glaucoma Prevention Study (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Valter Torri?
Valter Torri is affiliated with the following schools:
